Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,426 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Clear all
Completed Not applicable Interventional

eRT Remote Health Monitoring

NCT01495780
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Chronic Obstructive Lung Disease, Bronchitis, Chronic, Pulmonary Emphysema
Interventions
Remote Health Monitoring
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 4 Interventional

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions
Acalabrutinib, Investigator's choice of treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

NCT00818961
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
40 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional

"DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?"

NCT00238641
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Botulinum Toxin type B
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2005 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105
View directory record Official record
Conditions
Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

NCT02437422
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
SANGUINATE
Biological
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
View directory record Official record
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Completed No phase listed Observational

Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease

NCT00600951
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Not yet recruiting Phase 2 Interventional

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07582159
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Tafasitamab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Does Patient Testimonial Improve the Pain Relief Derived From a Brief Intervention

NCT07335159
View directory record Official record
Conditions
Pain, Acute Pain, Chronic Pain, Pain Management
Interventions
Pain Psychoeducation, Mindfulness
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building an Evidence Base for Weight Loss Strategies Among Those With Chronic SCI-The GLB-SCI+

NCT03874988
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
Interventions
Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Active, not recruiting Not applicable Interventional

A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia

NCT06579027
View directory record Official record
Conditions
Hemiplegia, Cerebral Palsy, Children, Only
Interventions
SPEED Training, CRAFT Training
Device · Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
3 Years to 8 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Does Reducing Spasticity Permit an Increase in Strength?

NCT00255073
View directory record Official record
Conditions
Spastic Diplegic Cerebral Palsy
Interventions
baclofen
Drug
Lead sponsor
University of Southern California
Other
Eligibility
5 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402
View directory record Official record
Conditions
Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions
Barzolvolimab, Matching Placebo
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

NCT04410146
View directory record Official record
Conditions
Subdural Hematoma, Chronic
Interventions
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Standard Medical Management
Device · Procedure · Other
Lead sponsor
Balt USA
Industry
Eligibility
30 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

NCT00449761
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 5, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma

NCT00645970
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement

NCT01188551
View directory record Official record
Conditions
Chronic Otitis Media
Interventions
Dexmedetomidine, Fentanyl, Midazolam
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Cannabidiol, Morphine, Pain

NCT04030442
View directory record Official record
Conditions
CBD, Chronic Pain
Interventions
Immediate-release Oral Morphine Sulfate Tablets, Thermal and Pressure Nociceptive Sensitivity
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

NCT00355342
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Not applicable Interventional

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

NCT05569005
View directory record Official record
Conditions
COPD, Smoking, Tobacco Use
Interventions
THS use, Cigarette, Smoking Abstinence
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
35 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
81
States / cities
Brandon, Florida • Cape Coral, Florida • Clearwater, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 5, 2026, 5:22 AM EDT